Table 2. Crude and adjusted area under the ROC curve (AUC) values by cancer site.

Area under the ROC curve (AUC). Cancer vs. normal tissue*
	Average methylation percentage across all 27 CpGs				Methylation percentage of GHSR_−1620			Average methylation percentage across four most hypermethylated consecutive CpGs in exon 1**
Malignancy	n	Crude	(95% CI)	Age-adjusted	Crude	(95% CI)	Age-adjusted	Crude	(95% CI)	Age-adjusted
Breast	20	0.9400	0.8181–1.0000	0.9800	0.9800	0.9329–1.0000	1.0000	0.9900	0.9623–1.0000	1.0000
Lung	29	0.9905	0.9679–1.0000	0.9952	1.0000	1.0000–1.0000	0.9692	0.9762	0.9263–1.0000	0.9952
Pancreas	18	1.0000	1.0000–1.0000	1.0000	1.0000	1.0000–1.0000	1.0000	1.0000	1.0000–1.0000	1.0000
Colorectum	33	0.7976	0.6406–0.9546	0.8095	0.6726	0.4815–0.8637	0.7341	0.8016	0.6469–0.9562	0.8492
Prostate	17	0.8667	0.6320–1.0000	0.8833	0.9667	0.8879–1.0000	0.9667	0.8909	0.6683–1.0000	0.8909
CLL	15	0.9400	0.8123–1.0000	NC	0.9600	0.8681–1.0000	NC	0.5600	0.2420–0.8779	NC
All cancers	132	0.8789	0.8206–0.9372	0.8862	0.8640	0.8001–0.9280	0.8776	0.8759	0.8177–0.9341	0.8907

NC: Not calculable. Brain samples were not included in the analysis due to the lack of normal tissues.

^*For CLL, B cells of healthy donors were employed as control.

^**GHSR_+249, GHSR_+251, GHSR_+257, GHSR_+259 were considered